37,675 reports of this reaction
4.8% of all DUPILUMAB reports
#2 most reported adverse reaction
DERMATITIS ATOPIC is the #2 most commonly reported adverse reaction for DUPILUMAB, manufactured by sanofi-aventis U.S. LLC. There are 37,675 FDA adverse event reports linking DUPILUMAB to DERMATITIS ATOPIC. This represents approximately 4.8% of all 782,562 adverse event reports for this drug.
Patients taking DUPILUMAB who experience dermatitis atopic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DERMATITIS ATOPIC is moderately reported among DUPILUMAB users, representing a notable but not dominant share of adverse events.
In addition to dermatitis atopic, the following adverse reactions have been reported for DUPILUMAB:
The following drugs have also been linked to dermatitis atopic in FDA adverse event reports:
DERMATITIS ATOPIC has been reported as an adverse event in 37,675 FDA reports for DUPILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DERMATITIS ATOPIC accounts for approximately 4.8% of all adverse event reports for DUPILUMAB, making it one of the most commonly reported side effect.
If you experience dermatitis atopic while taking DUPILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.